Zobrazeno 1 - 10
of 317
pro vyhledávání: '"Daniel J Renouf"'
Autor:
Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patient
Externí odkaz:
https://doaj.org/article/97b2590c6c9344189d1570b29cf64695
Publikováno v:
Biomarker Insights, Vol 16 (2021)
Biobanking efforts, to establish and grow the pool of available tissue from which evidence on aetiology, therapeutic susceptibility and prognosis of various diseases, have been underway for decades. This is illustrated nowhere better than in cancer.
Externí odkaz:
https://doaj.org/article/b91ee6ed509344bab1b5753ed55e0e5f
Autor:
Hassan A. Ali, Joanna M. Karasinska, James T. Topham, Danisha Johal, Steve Kalloger, Andrew Metcalfe, Cassia S. Warren, Anthony Miyagi, Lan V. Tao, Maya Kevorkova, Shawn C. Chafe, Paul C. McDonald, Shoukat Dedhar, Seth J. Parker, Daniel J. Renouf, David F. Schaeffer
Publikováno v:
Cancer & Metabolism, Vol 12, Iss 1, Pp 1-13 (2024)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease characterized by complex metabolic rewiring that enables growth in changing nutrient availability and oxygen conditions. Transcriptome-based prognostic PDAC tu
Externí odkaz:
https://doaj.org/article/a2c84c9d9241460d889b4c891a5bea32
Autor:
Emma Titmuss, Irene S. Yu, Erin D. Pleasance, Laura M. Williamson, Karen Mungall, Andrew J. Mungall, Daniel J. Renouf, Richard Moore, Steven J. M. Jones, Marco A. Marra, Janessa J. Laskin, Kerry J. Savage
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1865-1875 (2024)
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations. However, patients may exhibit significant immune-related adverse events (irAEs) that may lead
Externí odkaz:
https://doaj.org/article/165bce1a3d6f4c00a9c7740f49ec203b
Autor:
Erica S. Tsang, Veronika Csizmok, Laura M. Williamson, Erin Pleasance, James T. Topham, Joanna M. Karasinska, Emma Titmuss, Intan Schrader, Stephen Yip, Basile Tessier-Cloutier, Karen Mungall, Tony Ng, Sophie Sun, Howard J. Lim, Jonathan M. Loree, Janessa Laskin, Marco A. Marra, Steven J. M. Jones, David F. Schaeffer, Daniel J. Renouf
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-12 (2023)
Abstract There is emerging evidence about the predictive role of homologous recombination deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies. We reviewed whole genome (WGS) and transcriptomic (RNA-Seq) data
Externí odkaz:
https://doaj.org/article/94cf2e36a62f41e6b8a8f4c6c8888bcf
Autor:
Jannat Pervin, Mohammad Asad, Shaolong Cao, Gun Ho Jang, Nikta Feizi, Benjamin Haibe-Kains, Joanna M. Karasinska, Grainne M. O’Kane, Steven Gallinger, David F. Schaeffer, Daniel J. Renouf, George Zogopoulos, Oliver F. Bathe
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease characterized by a diverse tumor microenvironment. The heterogeneous cellular composition of PDAC makes it challenging to study molecular features of tumor cells using extracts f
Externí odkaz:
https://doaj.org/article/ec92d12728a044ddbf9be245d2f7b7e0
Autor:
Emma Titmuss, Richard D. Corbett, Scott Davidson, Sanna Abbasi, Laura M. Williamson, Erin D. Pleasance, Adam Shlien, Daniel J. Renouf, Steven J. M. Jones, Janessa Laskin, Marco A. Marra
Publikováno v:
BMC Medical Genomics, Vol 15, Iss 1, Pp 1-7 (2022)
Abstract Background Tumor mutation burden (TMB) is a key characteristic used in a tumor-type agnostic context to inform the use of immune checkpoint inhibitors (ICI). Accurate and consistent measurement of TMB is crucial as it can significantly impac
Externí odkaz:
https://doaj.org/article/f18cf18e81814d8ebd141b899b6b1bbc
Autor:
Mélina Boutin, James T. Topham, Harriet Feilotter, Hagen F. Kennecke, Félix Couture, Mohammed Harb, Peter Kavan, Scott Berry, Howard J. Lim, John R. Goffin, Chaudhary Ahmad, Anthony Lott, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen, Jonathan M. Loree
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The number of somatic mutations detectable in circulating tumor DNA (ctDNA) is highly heterogeneous in metastatic colorectal cancer (mCRC). The optimal number of mutations required to assess disease kinetics is relevant and remains poorly
Externí odkaz:
https://doaj.org/article/e6eff85bf5f845bf871d3d8d86b0404b
Autor:
Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, James T. Topham, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina A. Kim, Pan Du, Shidong Jia, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Chris J O’Callaghan
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-8 (2022)
Metastatic pancreatic ductal adenocarcinoma (mPDAC) has limited therapeutic options and is associated with a poor prognosis. Here the authors report the results of a randomized phase II trial showing that combining checkpoint inhibitors (durvalumab a
Externí odkaz:
https://doaj.org/article/ccff0c483c6e49d4b8726cac04df8470
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Over a decade of sequencing-based genomics research has unveiled a diverse somatic mutation landscape across patients with pancreatic ductal adenocarcinoma (PDAC), and the identification of druggable mutations has aligned with the development of nove
Externí odkaz:
https://doaj.org/article/1ddefd65f35640d0bc553b7afe638b42